Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies

Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE EVTCY have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD).

  • Based on Evotec's proprietary comprehensive molecular datasets, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines.
  • The collaboration will utilize Evotec's PanOmics platform, which combines throughput proteomics, high throughput transcriptomics, and cell imaging with PanHunter, its data analysis platform.
  • Chinook will contribute drug discovery and development programs to the collaboration targeting rare kidney diseases such as IgA nephropathy and glomerular diseases.
  • Under the terms of the agreement, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities.
  • Chinook will be responsible for the clinical development and commercialization of product candidates.
  • Evotec will receive an undisclosed upfront payment, research funding, milestone payments, and tiered sales-based royalties.
  • Price Action: KDNY shares closed 1.7% higher at $16.54, and EVTCY closed 0.8% lower at 77.45 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareContractsSmall CapGeneralChronic Kidney Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!